- Available history
- No dated observations
- Data captured
IPO Date coverage
Replimune Group, Inc. (REPL). What the retained company guidance contains and how many periods can be scored.
- Legal name: Value Replimune Group, Inc..
- Ticker: Value REPL.
- Exchange: Value Nasdaq.
- IPO date: Value 23 Jul 2018.
| Measure | Value |
|---|---|
| Legal name | Replimune Group, Inc. |
| Ticker | REPL |
| Exchange | Nasdaq |
| IPO date | 23 Jul 2018 |
| Country of operation (business address) | United States |
| Final IPO prospectus | Form 424B4 filed 2018-07-23, accession 0001047469-18-005126 |
| Registration statement | Form S-1 filed 2018-06-22, accession 0001047469-18-004714 |
| Current registered country | Delaware, United States SEC EDGAR state of incorporation DE |
| Business address | 500 UNICORN PARK, WOBURN, Massachusetts, 01801, United States |
| Mailing address | 500 UNICORN PARK, WOBURN, Massachusetts, 01801, United States |
| Industry (SIC) | 2836 Biological Products, (No Diagnostic Substances) |
| Fiscal year end | 03-31 |
| Filer category | Non-accelerated filer<br>Smaller reporting company |
| Listed stock (Section 12(b)) | Common Stock, par value $0.001 per share · REPL · NASDAQ 10-Q filed 2026-08-14 cover |
| Shell company | No 10-Q filed 2026-08-14 cover |
| Smaller reporting company | Yes 10-Q filed 2026-08-14 cover |
| Emerging growth company | No 10-Q filed 2026-08-14 cover |
| Current in its reporting | Yes 10-Q filed 2026-08-14 cover |
| Well-known seasoned issuer | No 10-K filed 2026-06-29 cover |
| Voluntary filer | No 10-K filed 2026-06-29 cover |
| First EDGAR filing | 2018-05-03 (DRS) |
| SEC CIK | 1737953 |
| EIN | 822082553 |
| Phone | (781) 222-9600 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B |